Literature DB >> 19100997

Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.

Richard A Rudick1, Jar-Chi Lee, Kunio Nakamura, Elizabeth Fisher.   

Abstract

BACKGROUND: Gray matter (GM) pathology is an important component of the multiple sclerosis (MS) disease process. Accelerated gray matter atrophy has been observed in MS patients, but its relationship to neurological disability is not defined. This study was done to determine the relationship between whole brain, GM, and white matter (WM) atrophy and MS disability progression.
METHODS: Patients with MS and Clinically Isolated Syndromes (CIS), and age- and gender-matched healthy controls were entered into an observational protocol. Baseline brain parenchymal fraction (BPF), GM fraction, and WM fraction, and change over 4 years were correlated with sustained disability progression over the entire study duration. Disability progression was measured using the Multiple Sclerosis Functional Composite (MSFC) and the Expanded Disability Status Scale (EDSS).
RESULTS: Seventy MS and CIS patients and 17 HCs were studied for an average of 6.6 years (range, 3.6-7.8 years). At the final visit, 7 patients were classified as CIS, 36 as relapsing-remitting MS (RRMS), and 27 as secondary progressive MS (SPMS). Baseline whole brain, GM, and WM atrophy predicted EDSS >6.0 at the last study visit. Twenty-one (33%) patients worsened using the EDSS to define disability progression; 29 (46%) worsened using MSFC to define disability progression. Patients with MSFC progression had significantly higher GM atrophy rates compared with patients who were stable on MSFC. White matter atrophy was similar in patients with and without disability progression. Atrophy rates were not different in patients with or without disability progression defined using EDSS.
CONCLUSIONS: Whole brain, GM, and WM atrophy predicted MS disability progression observed over the next 6.6 years. Gray matter atrophy rates over 4 years correlated with disability progression measured with the MSFC, but not EDSS. This indicates that MSFC defined disability progression is more closely linked to brain atrophy than EDSS defined disability progression, and provides important new insight into the poor correlation between MRI and clinical disability in MS. The findings confirm the clinical relevance of gray matter atrophy in MS.

Entities:  

Mesh:

Year:  2008        PMID: 19100997      PMCID: PMC2726444          DOI: 10.1016/j.jns.2008.11.018

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  32 in total

1.  Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter.

Authors:  Y Ge; R I Grossman; J K Udupa; J S Babb; L G Nyúl; D L Kolson
Journal:  Radiology       Date:  2001-09       Impact factor: 11.105

2.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

Authors:  J W Peterson; L Bö; S Mörk; A Chang; B D Trapp
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

3.  Eight-year follow-up study of brain atrophy in patients with MS.

Authors:  E Fisher; R A Rudick; J H Simon; G Cutter; M Baier; J-C Lee; D Miller; B Weinstock-Guttman; M K Mass; D S Dougherty; N A Simonian
Journal:  Neurology       Date:  2002-11-12       Impact factor: 9.910

4.  Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.

Authors:  Nynke F Kalkers; Najim Ameziane; Joost C J Bot; Arjan Minneboo; Chris H Polman; Frederik Barkhof
Journal:  Arch Neurol       Date:  2002-10

5.  Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.

Authors:  E Fisher; R A Rudick; G Cutter; M Baier; D Miller; B Weinstock-Guttman; M K Mass; D S Dougherty; N A Simonian
Journal:  Mult Scler       Date:  2000-12       Impact factor: 6.312

6.  Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.

Authors:  Catherine M Dalton; Declan T Chard; Gerard R Davies; Katherine A Miszkiel; Dan R Altmann; Kryshani Fernando; Gordon T Plant; Alan J Thompson; David H Miller
Journal:  Brain       Date:  2004-03-03       Impact factor: 13.501

7.  Detection of ventricular enlargement in patients at the earliest clinical stage of MS.

Authors:  P A Brex; R Jenkins; N C Fox; W R Crum; J I O'Riordan; G T Plant; D H Miller
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

8.  The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

Authors:  P D Molyneux; L Kappos; C Polman; C Pozzilli; F Barkhof; M Filippi; T Yousry; D Hahn; K Wagner; M Ghazi; K Beckmann; F Dahlke; N Losseff; G J Barker; A J Thompson; D H Miller
Journal:  Brain       Date:  2000-11       Impact factor: 13.501

Review 9.  Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.

Authors:  David H Miller; Frederik Barkhof; Joseph A Frank; Geoffrey J M Parker; Alan J Thompson
Journal:  Brain       Date:  2002-08       Impact factor: 13.501

10.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

Authors:  D T Chard; C M Griffin; G J M Parker; R Kapoor; A J Thompson; D H Miller
Journal:  Brain       Date:  2002-02       Impact factor: 13.501

View more
  46 in total

Review 1.  Current and new directions in MRI in multiple sclerosis.

Authors:  Eric C Klawiter
Journal:  Continuum (Minneap Minn)       Date:  2013-08

Review 2.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

3.  Can we overcome the 'clinico-radiological paradox' in multiple sclerosis?

Authors:  Kerstin Hackmack; Martin Weygandt; Jens Wuerfel; Caspar F Pfueller; Judith Bellmann-Strobl; Friedemann Paul; John-Dylan Haynes
Journal:  J Neurol       Date:  2012-03-24       Impact factor: 4.849

4.  A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis.

Authors:  J Furby; T Hayton; D Altmann; R Brenner; J Chataway; K J Smith; D H Miller; R Kapoor
Journal:  J Neurol       Date:  2010-05-01       Impact factor: 4.849

5.  Normal appearing white matter permeability: a marker of inflammation and information processing speed deficit among relapsing remitting multiple sclerosis patients.

Authors:  Eldar Eftekhari; Seyed-Parsa Hojjat; Rita Vitorino; Timothy J Carroll; Charles Grady Cantrell; Liesly Lee; Matthew W Taylor; Sarah A Morrow; Haddas Benhabib; Richard I Aviv; Andrea Kassner
Journal:  Neuroradiology       Date:  2017-06-16       Impact factor: 2.804

6.  SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Authors:  Riley Bove; Tanuja Chitnis; Bruce Ac Cree; Mar Tintoré; Yvonne Naegelin; Bernard Mj Uitdehaag; Ludwig Kappos; Samia J Khoury; Xavier Montalban; Stephen L Hauser; Howard L Weiner
Journal:  Mult Scler       Date:  2017-08-29       Impact factor: 6.312

Review 7.  The importance of studying sex differences in disease: The example of multiple sclerosis.

Authors:  Lisa C Golden; Rhonda Voskuhl
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

8.  Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.

Authors:  Kimberly M Winges; John S Werner; Danielle J Harvey; Kimberly E Cello; Mary K Durbin; Laura J Balcer; Peter A Calabresi; John L Keltner
Journal:  J Neuroophthalmol       Date:  2013-12       Impact factor: 3.042

Review 9.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

10.  Cortical remyelination: a new target for repair therapies in multiple sclerosis.

Authors:  Ansi Chang; Susan M Staugaitis; Ranjan Dutta; Courtney E Batt; Kathryn E Easley; Anthony M Chomyk; V Wee Yong; Robert J Fox; Grahame J Kidd; Bruce D Trapp
Journal:  Ann Neurol       Date:  2012-10-17       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.